CNBC
•90% Informative
Dominant weight loss drugmakers Novo Nordisk and Eli Lilly are showing encouraging progress in their efforts to increase supply.
Some Wall Street analysts project that the weight- Novo Nordisk rket Eli Lilly worth $100 billion by the end of the decade.
Both companies have given positive supply updates, aiming to reassure investors that they can capitalize on the success of their drugs.
Eli Lilly says a new plant in North Carolina will start production of incretin drugs as early as the end of the year.
Novo Nordisk k and Eli Lilly y have poured billions into building new production sites that could boost supply.
Alternative forms of weight loss and diabetes drugs could also help alleviate supply constraints. 20 a few years Cantor Fitzgerald ">Eli Lil Louise Chen CNBC s="summaryFeed_highLightText__NxlGi">Novo Nordisk's 36 weeks Novo Nordisk's " Wegovy and a Eli Lilly's l Zepbound maryFeed_highLightText__NxlGi">obese Eli Lilly's Eli Lil Goldman Sachs pan class="summar 15 million L U.S. Text__NxlGi">2025 2030 ryFeed_highLightText__NxlGi">U.S. $100 billion the end of the decade maryFeed_highLightText__NxlGi">Eli Lilly last month Mohit Bansal Wells Fargo fou the summer Jeff Friedman highLightText__NxlGi">month
VR Score
91
Informative language
91
Neutral language
81
Article tone
formal
Language
English
Language complexity
56
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
9
Source diversity
7
Affiliate links
no affiliate links